المؤلفون: Ascierto, PA, Casula, M, Bulgarelli, J, Pisano, M, Piccinini, C, Piccin, L, Cossu, A, Mandalà, M, Ferrucci, PF, Guidoboni, M, Rutkowski, P, Ferraresi, V, Arance, A, Guida, M, Maiello, E, Gogas, H, Richtig, E, Fierro, MT, Lebbe, C, Helgadottir, H, Queirolo, P, Spagnolo, F, Tucci, M, Del Vecchio, M, Cao, MG, Minisini, AM, De Placido, S, Sanmamed, MF, Mallardo, D, Paone, M, Vitale, MG, Melero, I, Grimaldi, AM, Giannarelli, D, Dummer, R, Sileni, VC, Palmieri, G

المصدر: Nature communications. 15(1):146

مصطلحات موضوعية: Medicin och hälsovetenskap

الوصول الحر: http://kipublications.ki.se/Default.aspx?queryparsed=id:238167503Test

المؤلفون: Faoro, L., Salizzato, V., Coppola, M., Carpanese, D., Fabozzi, A., Tondulli, L., Marconcini, R., Spagnolo, F., Del Bianco, P., Chiarion‐Sileni, V., Piccin, L.

المساهمون: Istituto Oncologico Veneto

المصدر: Journal of the European Academy of Dermatology and Venereology ; ISSN 0926-9959 1468-3083

الإتاحة: https://doi.org/10.1111/jdv.20066Test

المؤلفون: Rastrelli M., Del Fiore P., Russo I., Tartaglia J., Dal Monico A., Cappellesso R., Nicole L., Piccin L., Fabozzi A., Biffoli B., Di Prata C., Ferrazzi B., Dall'Olmo L., Vecchiato A., Spina R., Russano F., Bezzon E., Cingarlini S., Mazzarotto R., Parisi A., Scarzello G., Pigozzo J., Brambullo T., Tropea S., Vindigni V., Bassetto F., Bertin D., Gregianin M., Dei Tos A. P., Cavallin F., Alaibac M., Chiarion-Sileni V., Mocellin S.

المساهمون: Rastrelli, M., Del Fiore, P., Russo, I., Tartaglia, J., Dal Monico, A., Cappellesso, R., Nicole, L., Piccin, L., Fabozzi, A., Biffoli, B., Di Prata, C., Ferrazzi, B., Dall'Olmo, L., Vecchiato, A., Spina, R., Russano, F., Bezzon, E., Cingarlini, S., Mazzarotto, R., Parisi, A., Scarzello, G., Pigozzo, J., Brambullo, T., Tropea, S., Vindigni, V., Bassetto, F., Bertin, D., Gregianin, M., Dei Tos, A. P., Cavallin, F., Alaibac, M., Chiarion-Sileni, V., Mocellin, S.

مصطلحات موضوعية: Merkel carcinoma, Merkel cell cancer, Merkel treatment strategie, non-melanoma skin cancer (NMSC), skin cancer

الوصف: Background: Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin. The incidence of the disease has undergone a significant increase in recent years, which is caused by an increase in the average age of the population and in the use of immunosuppressive therapies. MCC is an aggressive pathology, which metastasizes early to the lymph nodes. These characteristics impose an accurate diagnostic analysis of the regional lymph node district with radiography, clinical examination and sentinel node biopsy. In recent years, there has been a breakthrough in the treatment of the advanced pathology thanks to the introduction of monoclonal antibodies acting on the PD-1/PD-L1 axis. This study aimed to describe the clinico-pathological characteristics, treatment strategies and prognostic factors of MCC. Methods: A retrospective cohort study was conducted involving 143 consecutive patients who were diagnosed and/or treated for MCC. These patients were referred to the Veneto Institute of Oncology IOV-IRCCS and to the University Hospital of Padua (a third-level center) in the period between December 1991 and January 2020. In the majority of cases, diagnosis took place at the IOV. However, some patients were diagnosed elsewhere and subsequently referred to the IOV for a review of the diagnosis or to begin specific therapeutic regimens. Results: 143 patients, with an average age of 71 years, were affected mainly with autoimmune and neoplastic comorbidities. Our analysis has shown that age, autoimmune comorbidities and the use of therapy with immunomodulating drugs (which include corticosteroids, statins and beta-blockers) are associated with a negative prognosis. In this sense, male sex is also a negative prognostic factor. Conclusions: Autoimmune and neoplastic comorbidities were frequent in the studied population. The use of drugs with immunomodulatory effects was also found to be a common feature of the population under examination. The use of this type of medication is considered a negative prognostic factor. ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34976795; info:eu-repo/semantics/altIdentifier/wos/WOS:000738466200001; volume:11; firstpage:737842; numberofpages:10; journal:FRONTIERS IN ONCOLOGY; http://hdl.handle.net/11577/3410860Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85122104340; https://zenodo.org/record/5833513#.YdwgsVnSKUkTest

الإتاحة: https://doi.org/10.3389/fonc.2021.737842Test
http://hdl.handle.net/11577/3410860Test
https://zenodo.org/record/5833513#.YdwgsVnSKUkTest

المؤلفون: Ottaviano, M, Curvietto, M, Rescigno, P, Tortora, M, Palmieri, G, Giannarelli, D, Aieta, M, Assalone, P, Attademo, L, Avallone, A, Bloise, F, Bosso, D, Borzillo, V, Buono, G, Calderoni, G, Caputo, F, Cartenì, G, Cavallero, D, Cavo, A, Ciardiello, F, Conca, R, Conteduca, V, De Falco, S, De Felice, M, De Laurentiis, M, De Placido, P, De Placido, S, De Santo, I, De Stefano, A, Della Corte, CM, Di Franco, R, Di Lauro, V, Fabbrocini, A, Federico, P, Festino, L, Giordano, P, Giuliano, M, Gridelli, C, Grimaldi, AM, Lia, M, Marretta, AL, Massa, V, Mennitto, A, Merler, S, Merz, V, Messina, C, Messina, M, Milano, M, Minisini, AM, Montesarchio, V, Morabito, A, Morgillo, F, Mucci, B, Nappi, L, Napolitano, F, Paciolla, I, Pagliuca, M, Parola, S, Pepe, S, Petrillo, A, Piantedosi, F, Piccin, L, Picozzi, F, Pietroluongo, E, Pignata, S, Prati, V, Riccio, V, Rosanova, M, Rossi, A, Russo, A, Salati, M, Santabarbara, G, Sbrana, A, Simeone, E, Silvestri, A, Spada, M, Tarantino, P, Taveggia, P, Tomei, F, Vincenzo, T, Trapani, D, Trojanello, C, Vanella, V, Vari, S, Ventriglia, J, Vitale, MG, Vitiello, F, Vivaldi, C, von Arx, C, Zacchi, F, Zampiva, I, Zivi, A, Daniele, B, Ascierto, PA, SCITO (Società Campana di ImmunoTerapia Oncologica)

المساهمون: Rescigno, Pasquale

مصطلحات موضوعية: SCITO (Società Campana di ImmunoTerapia Oncologica), Humans, Pneumonia, Viral, Coronavirus Infections, Neoplasms, Prevalence, Medical Oncology, Infection Control, Geography, Adult, Italy, Female, Male, Drug Prescriptions, Pandemics, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Time-to-Treatment, Surveys and Questionnaires, Practice Patterns, Physicians', Oncologists, Betacoronavirus, Antineoplastic Agents, Immunological, B7-H1 Antigen, COVID-19, SARS-CoV-2

الوصف: BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. METHODS: This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options. RESULTS: This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. CONCLUSION: Our study highlights the efforts of Italian oncologists to maintain high standards of care ...

وصف الملف: Print; application/pdf

العلاقة: Journal for immunotherapy of cancer, 2020, 8 (2); https://repository.icr.ac.uk/handle/internal/4346Test

الإتاحة: https://doi.org/10.1136/jitc-2020-001154Test
https://repository.icr.ac.uk/handle/internal/4346Test

المؤلفون: Pavan, A., Calvetti, L., Dal Maso, A., Fabozzi, A., Piccin, L., Chiarion-Sileni, V., Pasello, G., Aprile, G., Guarneri, V., Conte, P.F., Bonanno, L.

المصدر: Annals of Oncology ; volume 30, page v45 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1093/annonc/mdz239.054Test
https://api.elsevier.com/content/article/PII:S0923753419583739?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753419583739?httpAccept=text/plainTest
http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz239.054/30082396/mdz239.054.pdfTest

المؤلفون: Ottaviano M., Curvietto M., Rescigno P., Tortora M., Palmieri G., Giannarelli D., Aieta M., Assalone P., Attademo L., Avallone A., Bloise F., Bosso D., Borzillo V., Buono G., Calderoni G., Caputo F., Carteni G., Cavallero D., Cavo A., Ciardiello F., Conca R., Conteduca V., De Falco S., De Felice M., De Laurentiis M., De Placido P., De Placido S., De Santo I., De Stefano A., Della Corte C. M., Di Franco R., Di Lauro V., Fabbrocini A., Federico P., Festino L., Giordano P., Giuliano M., Gridelli C., Grimaldi A. M., Lia M., Marretta A. L., Massa V., Mennitto A., Merler S., Merz V., Messina C., Messina M., Milano M., Minisini A. M., Montesarchio V., Morabito A., Morgillo F., Mucci B., Nappi L., Napolitano F., Paciolla I., Pagliuca M., Parola S., Pepe S., Petrillo A., Piantedosi F., Piccin L., Picozzi F., Pietroluongo E., Pignata S., Prati V., Riccio V., Rosanova M., Rossi A., Russo A., Salati M., Santabarbara G., Sbrana A., Simeone E., Silvestri A., Spada M., Tarantino P., Taveggia P., Tomei F., Vincenzo T., Trapani D., Trojanello C., Vanella V., Vari S., Ventriglia J., Vitale M. G., Vitiello F., Vivaldi C., Von Arx C., Zacchi F., Zampiva I., Zivi A., Daniele B., Ascierto P. A.

المساهمون: Ottaviano, M., Curvietto, M., Rescigno, P., Tortora, M., Palmieri, G., Giannarelli, D., Aieta, M., Assalone, P., Attademo, L., Avallone, A., Bloise, F., Bosso, D., Borzillo, V., Buono, G., Calderoni, G., Caputo, F., Carteni, G., Cavallero, D., Cavo, A., Ciardiello, F., Conca, R., Conteduca, V., De Falco, S., De Felice, M., De Laurentiis, M., De Placido, P., De Placido, S., De Santo, I., De Stefano, A., Della Corte, C. M., Di Franco, R., Di Lauro, V., Fabbrocini, A., Federico, P., Festino, L., Giordano, P., Giuliano, M., Gridelli, C., Grimaldi, A. M., Lia, M., Marretta, A. L., Massa, V., Mennitto, A., Merler, S., Merz, V., Messina, C., Messina, M., Milano, M., Minisini, A. M., Montesarchio, V., Morabito, A., Morgillo, F., Mucci, B., Nappi, L., Napolitano, F., Paciolla, I., Pagliuca, M., Parola, S., Pepe, S., Petrillo, A., Piantedosi, F., Piccin, L., Picozzi, F., Pietroluongo, E., Pignata, S., Prati, V., Riccio, V., Rosanova, M., Rossi, A., Russo, A., Salati, M., Santabarbara, G., Sbrana, A., Simeone, E., Silvestri, A., Spada, M., Tarantino, P., Taveggia, P., Tomei, F., Vincenzo, T., Trapani, D., Trojanello, C., Vanella, V., Vari, S., Ventriglia, J., Vitale, M. G., Vitiello, F., Vivaldi, C., Von Arx, C., Zacchi, F., Zampiva, I., Zivi, A., Daniele, B., Ascierto, P. A.

مصطلحات موضوعية: antineoplastic protocol, healthcare economics and organization, immunotherapy, lung neoplasm, melanoma, Adult, Antineoplastic Agents, Immunological, B7-H1 Antigen, Betacoronaviru, COVID-19, CTLA-4 Antigen, Coronavirus Infection, Drug Prescription, Female, Geography, Human, Infection Control, Italy, Male, Medical Oncology, Neoplasm, Oncologist, Pandemic, Pneumonia, Viral, Practice Patterns, Physicians', Prevalence, Programmed Cell Death 1 Receptor

الوصف: Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. Methods This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ 2 test for trends relative to the questions with 3 or more options. Results This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. Conclusion Our study highlights the efforts of Italian oncologists to maintain high standards of care ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33060148; info:eu-repo/semantics/altIdentifier/wos/WOS:000583157800005; volume:8; firstpage:e001154; lastpage:e001154; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; http://hdl.handle.net/11386/4756291Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85093476336

الإتاحة: https://doi.org/10.1136/jitc-2020-001154Test
http://hdl.handle.net/11386/4756291Test

المؤلفون: Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Cartenì G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA, SCITO (Società Campana di ImmunoTerapia Oncologica).

المساهمون: Ottaviano, M, Curvietto, M, Rescigno, P, Tortora, M, Palmieri, G, Giannarelli, D, Aieta, M, Assalone, P, Attademo, L, Avallone, A, Bloise, F, Bosso, D, Borzillo, V, Buono, G, Calderoni, G, Caputo, F, Cartenì, G, Cavallero, D, Cavo, A, Ciardiello, F, Conca, R, Conteduca, V, De Falco, S, De Felice, M, De Laurentiis, M, De Placido, P, De Placido, S, De Santo, I, De Stefano, A, Della Corte, Cm, Di Franco, R, Di Lauro, V, Fabbrocini, A, Federico, P, Festino, L, Giordano, P, Giuliano, M, Gridelli, C, Grimaldi, Am, Lia, M, Marretta, Al, Massa, V, Mennitto, A, Merler, S, Merz, V, Messina, C, Messina, M, Milano, M, Minisini, Am, Montesarchio, V, Morabito, A, Morgillo, F, Mucci, B, Nappi, L, Napolitano, F, Paciolla, I, Pagliuca, M, Parola, S, Pepe, S, Petrillo, A, Piantedosi, F, Piccin, L, Picozzi, F, Pietroluongo, E, Pignata, S, Prati, V, Riccio, V, Rosanova, M, Rossi, A, Russo, A, Salati, M, Santabarbara, G, Sbrana, A, Simeone, E, Silvestri, A, Spada, M, Tarantino, P, Taveggia, P, Tomei, F, Vincenzo, T, Trapani, D, Trojanello, C, Vanella, V, Vari, S, Ventriglia, J, Vitale, Mg, Vitiello, F, Vivaldi, C, von Arx, C, Zacchi, F, Zampiva, I, Zivi, A, Daniele, B, Ascierto, Pa, SCITO (Società Campana di ImmunoTerapia, Oncologica).

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000583157800005; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; http://hdl.handle.net/11369/407892Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85093476336

الإتاحة: http://hdl.handle.net/11369/407892Test

المؤلفون: Valpione, S., Bazzi, M., Piccin, L., Pigozzo, J., Chiarion-Sileni, V.

المصدر: Annals of Oncology ; volume 25, page iv380 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1093/annonc/mdu344.14Test
https://api.elsevier.com/content/article/PII:S0923753419525042?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753419525042?httpAccept=text/plainTest
http://academic.oup.com/annonc/article-pdf/25/suppl_4/iv380/9691265/mdu344.14.pdfTest

المؤلفون: Frezzini, S., Giarratano, T., Griguolo, G., Piccin, L., Mioranza, E., Giorgi, C. A., Menichetti, A., Miglietta, F., Genovesi, E., Cumerlato, E., Bottosso, M., Angelini, S., Vernaci, G., Dieci, M. V., V. Guarneri.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______3657::917c37a13e2a8353749cd7eda6d93c98Test
https://hdl.handle.net/11577/3462335Test

المؤلفون: Valpione, Sara, Pasquali, S, Campana, L, Piccin, L, Mocellin, S, Pigozzo, J, Chiarion-Sileni, V

المساهمون: CRUK Manchester Institute and The Christie NHS Foundation Trust, The University of Manchester, Manchester, M20 4GJ

الوصف: Ipilimumab is a licensed immunotherapy for metastatic melanoma patients and, in the US, as adjuvant treatment for high risk melanoma radically resected. The use of ipilimumab is associated with a typical but unpredictable pattern of side effects. The purpose of this study was to identify clinical features and blood biomarkers capable of predicting ipilimumab related toxicity.

العلاقة: Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. 2018, 16(1): 94 J Transl Med; http://hdl.handle.net/10541/621000Test; Journal of Translational Medicine

الإتاحة: https://doi.org/10.1186/s12967-018-1467-xTest
http://hdl.handle.net/10541/621000Test